Alto Neuroscience, Inc.
NYSE:ANROBiotechnology
+$0.40 today
- Market cap
- $1.04B
- Beta
- 1.25
- P/E (TTM)
- -9.8
- EPS (TTM)
- -$2.26
Volume 0.99M
Average 0.34M
Returns on capital
Alto Neuroscience, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-41.8%
avg 22.8%
ROIC
-38.2%
avg -46.8%
ROA
-34.2%
avg -39.4%
Analysis
ROA is currently the strongest return metric at -34.2% versus its period average of -39.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Amit Etkin | Founder, CEO & Chairman of the Board | USD 1.25M | 49 | 833.95K | 2.38% |
Nicholas C. Smith | CFO & President | USD 946.86K | 37 | — | — |
Michael C. Hanley | Chief Operating Officer | USD 695.33K | 52 | — | — |
Adam Savitz | Chief Medical Officer | USD 579.57K | 60 | 124.00K | 0.35% |
Dan Segal | Co-Founder & Strategic Advisor | — | 64 | — | — |
Erin R. McQuade | General Counsel, Chief Administrative Officer & Corporate Secretary | — | 51 | — | — |
Jessica Powell | Chief Development Officer | — | 51 | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding May 14, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
3
$3.57M
Net Transaction Value
−$3.57M
Net selling
Most Active
Smith Nicholas Conrad
3 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Sep 30, 26Sep 30, 2026 | Smith Nicholas Conrad Direct | Sell | $597.3K$597,290.16 |
| Sep 30, 26Sep 30, 2026 | Smith Nicholas Conrad Direct | Sell | $23.8K$23,806.82 |
| Sep 29, 26Sep 29, 2026 | Smith Nicholas Conrad Direct | Sell | $2.9M$2,946,149.56 |
Summary
Insiders reported 0 buys worth $0.00 and 3 sells worth $3.57M over the last 12 months. That adds up to net selling of $3.57M. Smith Nicholas Conrad was the most active insider with 3 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | N/A | N/A6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Alto Neuroscience, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about ANRO's management, answered from reported figures.
Who manages ANRO?
Alto Neuroscience, Inc. (ANRO) lists 7 active executives. The top listed executive is Amit Etkin, Founder, CEO & Chairman of the Board.
Are ANRO insiders buying or selling?
Recent insider activity shows net buying of $25.65M.
Continue the stock analysis
Jump to another research area for this company.